PALO ALTO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex or the Company), an innovative revenue-generating company focused on acquiring, developing and...
PALO ALTO, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex or Company), an innovative revenue-generating company focused on acquiring, developing and...
Launching Co-Pay programs for ZTlido® and ELYXYB® for commercially insured patientsMulti-State Medicaid Pharmaceutical Purchasing Group added ELYXYB® to its purchasing pool PALO ALTO, Calif.,...
PALO ALTO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex), an innovative revenue-generating company focused on acquiring, developing and commercializing...
PALO ALTO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex or Company), an innovative revenue-generating company focused on acquiring, developing and...
PALO ALTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex), an innovative revenue-generating company focused on acquiring, developing and commercializing...
ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 According to market data from 2018, it...
Scilex Entered into a Agreement with Virpax Pharmaceuticals
Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product
Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba